Transcenta Therapeutics granted EirGenix a non‑exclusive license to its HiCB (highly intensified continuous bioprocessing) platform, including continuous perfusion and integrated hybrid purification technologies. The deal covers process documentation, regulatory support packages and entitles Transcenta to upfront, milestone and royalty payments. EirGenix will apply HiCB to support CDMO clients seeking intensified biologics manufacturing. Transcenta framed the move as a commercialization and scale strategy to expand global access to biologics while monetizing its process innovations.